Potential antitumor effect of polysaccharides extracted from <em>Polygonatum sibiricum</em> on human prostate cancer PC‑3 cells

Zhao,Guobin; Zhou,Yan; Tang,Yuhong; Abbas,Muhammad; Dong,Shaowen; Zhao,Xinyang; Liu,Xin; Wang,Xinmei; Li,Chen; Liu,Chenxi

doi:10.3892/ol.2024.14774

Potential antitumor effect of polysaccharides extracted from Polygonatum sibiricum on human prostate cancer PC‑3 cells

Authors:
- Guobin Zhao
- Yan Zhou
- Yuhong Tang
- Muhammad Abbas
- Shaowen Dong
- Xinyang Zhao
- Xin Liu
- Xinmei Wang
- Chen Li
- Chenxi Liu
View Affiliations

Affiliations: Department of Urology, The First Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei 075000, P.R. China, Department of Immunology, Hebei North University, Zhangjiakou, Hebei 075000, P.R. China, Department of Urology, The First Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei 075000, P.R. China, Graduate School, Hebei North University, Zhangjiakou, Hebei 075000, P.R. China
Published online on: October 25, 2024 https://doi.org/10.3892/ol.2024.14774
Article Number: 28
Copyright: © Zhao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Polygonatum sibiricum polysaccharides (PSP) are a traditional herbal medicine component with potential therapeutic effects on several diseases. The present study aimed to assess the role of PSP in the treatment of human prostate cancer using a PC‑3 cell line by Cell CK‑8, transwell and wound healing assays, then elucidate the potential underlying mechanisms by western blot and quantitative Real‑time RT‑PCR. Different concentrations of PSP were applied to PC‑3 cells, and the proliferation, invasion and migration of PC‑3 cells were demonstrated to be significantly inhibited with increasing concentrations of PSP. Additionally, cell apoptosis rate and expression of caspase‑3 increased with higher PSP concentrations, and the cell cycle was arrested in the S phase. Furthermore, it was demonstrated that the expression of the multidrug resistance‑1 gene and its encoded protein P‑glycoprotein in PC‑3 cells decreased following PSP treatment, suggesting that PSP may have the potential to reverse multidrug resistance in PC‑3 cells. The present study also evaluated the possible mechanism of PSP action on PC‑3 cells. The results revealed that phosphorylated P65, PI3K and AKT decreased in a concentration‑dependent manner. As key molecules in the NF‑κB and PI3K/Akt signaling pathways, this finding suggests that the potential mechanism of the effect of PSP on prostate cancer cells may involve simultaneous mediation of the PI3K/Akt and NF‑κB signaling pathways. The present study demonstrated that PSP inhibit the proliferation, invasion and migration of PC‑3 cells in vitro, as well as reverse MDR in these cells. The underlying mechanism may involve the simultaneous regulation of the PI3K/Akt and NF‑κB signaling pathways.

View Figures

View References

1	Silk N, Reich J, Sinha R, Chawla S, Geary K and Zhang D: The effects of resveratrol on prostate cancer through targeting the tumor microenvironment. J Xenobiot. 11:16–32. 2021. View Article : Google Scholar : PubMed/NCBI
2	Penezić L, Kuliš T, Hudolin T, Zekulić T, Saić H and Kaštelan Ž: Laparoscopic radical prostatectomy: Single center case series. Acta Clin Croat. 61 (Suppl 3):S15–S20. 2022.PubMed/NCBI
3	Stoykova GE and Schlaepfer IR: Lipid metabolism and endocrine resistance in prostate cancer, and new opportunities for therapy. Int J Mol Sci. 20:26262019. View Article : Google Scholar : PubMed/NCBI
4	Cai M, Song XL, Li XA, Chen M, Guo J, Yang DH, Chen Z and Zhao SC: Current therapy and drug resistance in metastatic castration-resistant prostate cancer. Drug Resist Updat. 68:1009622023. View Article : Google Scholar : PubMed/NCBI
5	Cui X, Wang S, Cao H, Guo H, Li Y, Xu F, Zheng M, Xi X and Han C: A Review: The bioactivities and pharmacological applications of polygonatumsibiricum polysaccharides. Molecules. 23:11702018. View Article : Google Scholar : PubMed/NCBI
6	Zhang H, Li H, Pan B, Zhang S, Su X, Sun W, Zhang T, Zhang Z, Lv S and Cui H: Integrated 16S rRNA sequencing and untargeted metabolomics analysis to reveal the protective mechanisms of polygonatum sibiricum polysaccharide on type 2 diabetes mellitus model rats. Curr Drug Metab. 24:270–282. 2023. View Article : Google Scholar : PubMed/NCBI
7	Wang Y, Lan C, Liao X, Chen D, Song W and Zhang Q: Polygonatum sibiricum polysaccharide potentially attenuates diabetic retinal injury in a diabetic rat model. J Diabetes Investig. 10:915–924. 2019. View Article : Google Scholar : PubMed/NCBI
8	Yang JX, Wu S, Huang XL, Hu XQ and Zhang Y: Hypolipidemic Activity and Anti-atherosclerotic Effect of Polysaccharide of Polygonatum sibiricum in Rabbit Model and Related Cellular Mechanisms. Evid Based Complement Alternat Med. 2015:3910652015. View Article : Google Scholar : PubMed/NCBI
9	Ye G, Zhao Y, Zhu J, Zhang Z, Wang Q, Jiang X and Wang Z: Synergistic effect of polydatin and polygonatum sibiricum polysaccharides in combating atherosclerosis via suppressing TLR4-Mediated NF-κB Activation in ApoE-Deficient Mice. Evid Based Complement Alternat Med. 2022:38851532022. View Article : Google Scholar : PubMed/NCBI
10	Du L, Nong MN, Zhao JM, Peng XM, Zong SH and Zeng GF: Polygonatum sibiricum polysaccharide inhibits osteoporosis by promoting osteoblast formation and blocking osteoclastogenesis through Wnt/β-catenin signaling pathway. Sci Rep. 6:322612016. View Article : Google Scholar : PubMed/NCBI
11	Long T, Liu Z, Shang J, Zhou X, Yu S, Tian H and Bao Y: Polygonatum sibiricum polysaccharides play anti-cancer effect through TLR4-MAPK/NF-kappaB signaling pathways. Int J Biol Macromol. 111:813–821. 2018. View Article : Google Scholar : PubMed/NCBI
12	Xu Y, Guo Y, Lu C, Yu L, Fang C and Li C: Polygonatum sibiricum polysaccharide inhibited liver cancer in a simulated tumor microenvironment by eliminating TLR4/STAT3 pathway. Biol Pharm Bull. 46:1249–1259. 2023. View Article : Google Scholar : PubMed/NCBI
13	Han SY, Hu MH, Qi GY, Ma CX, Wang YY, Ma FL, Tao N and Qin ZH: Polysaccharides from Polygonatum Inhibit the Proliferation of Prostate Cancer-Associated Fibroblasts. Asian Pac J Cancer Prev. 17:3829–3833. 2016.PubMed/NCBI
14	Li M, Liu Y, Zhang H, Liu Y, Wang W, You S, Hu X, Song M, Wu R and Wu J: Anti-cancer Potential of Polysaccharide Extracted From Polygonatum sibiricum on HepG2 cells via cell cycle arrest and apoptosis. Front Nutr. 9:9382902022. View Article : Google Scholar : PubMed/NCBI
15	Li L, Tian LN, Ren ZX and Long ZJ: Research progress on the structural analysis and functional activity of polysaccharides. Chin J Exp Tradit Med Fromul. 21:231–234. 2015.(In Chinese).
16	Tewari D, Patni P and Bishayee A, Sah AN and Bishayee A: Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: A novel therapeutic strategy. Semin Cancer Biol. 80:1–17. 2022. View Article : Google Scholar : PubMed/NCBI
17	Hashemi M, Taheriazam A, Daneii P, Hassanpour A, Kakavand A, Rezaei S, Hejazi ES, Aboutalebi M, Gholamrezaie H, Saebfar H, et al: Targeting PI3K/Akt signaling in prostate cancer therapy. J Cell Commun Signal. 17:423–443. 2023. View Article : Google Scholar : PubMed/NCBI
18	Wang Q, Wu S, Gu Y, Liang H, He F, Wang X, He D and Wu K: RASAL2 regulates the cell cycle and cyclin D1 expression through PI3K/AKT signalling in prostate tumorigenesis. Cell Death Discov. 8:2752022. View Article : Google Scholar : PubMed/NCBI
19	Gu Y and Liang C: TRAIP suppressed apoptosis and cell cycle to promote prostate cancer proliferation via TRAF2-PI3K-AKT pathway activation. Int Urol Nephrol. 56:1639–1648. 2024. View Article : Google Scholar : PubMed/NCBI
20	Raja Singh P, Sugantha Priya E, Balakrishnan S, Arunkumar R, Sharmila G, Rajalakshmi M and Arunakaran J: Inhibition of cell survival and proliferation by nimbolide in human androgen-independent prostate cancer (PC-3) cells: Involvement of the PI3K/Akt pathway. Mol Cell Biochem. 427:69–79. 2017. View Article : Google Scholar : PubMed/NCBI
21	Chen H, Zhou L, Wu X, Li R, Wen J, Sha J and Wen X: The PI3K/AKT pathway in the pathogenesis of prostate cancer. Front Biosci (Landmark Ed). 21:1084–1091. 2016. View Article : Google Scholar : PubMed/NCBI
22	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
23	Davoudi Z, Akbarzadeh A, Rahmatiyamchi M, Movassaghpour AA, Alipour M, Nejati-Koshki K, Sadeghi Z, Dariushnejad H and Zarghami N: Molecular Target Therapy of AKT and NF-kB Signaling Pathways and Multidrug Resistance by Specific Cell Penetrating Inhibitor Peptides in HL-60 Cells. Asian Pac J Cancer Prev. 15:4353–4358. 2014. View Article : Google Scholar : PubMed/NCBI
24	Duan C, Yu M, Xu J, Li BY, Zhao Y and Kankala RK: Overcoming Cancer Multi-drug Resistance (MDR): Reasons, mechanisms, nanotherapeutic solutions, and challenges. Biomed Pharmacother. 162:1146432023. View Article : Google Scholar : PubMed/NCBI
25	Liu D, Tang W, Han C and Nie S: Advances in Polygonatum sibiricum polysaccharides: Extraction, purification, structure, biosynthesis, and bioactivity. Front Nutr. 9:10746712022. View Article : Google Scholar : PubMed/NCBI
26	Ji Y, Li XY, Qi Y, Zhao J, Zhang W and Qu P: Anlotinib exerts inhibitory effects against cisplatin-resistant ovarian cancer in vitro and in vivo. Molecules. 27:88732022. View Article : Google Scholar : PubMed/NCBI
27	Liao YD, Grobholz R, Abel U, Trojan L, Michel MS, Angel P and Mayer D: Increase of AKT/PKB expression correlates with gleason pattern in human prostate cancer. Int J Cancer. 107:676–680. 2003. View Article : Google Scholar : PubMed/NCBI
28	Malik SN, Brattain M, Ghosh PM, Troyer DA, Prihoda T, Bedolla R and Kreisberg JI: Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin Cancer Res. 8:1168–1171. 2002.PubMed/NCBI
29	Lien EC, Dibble CC and Toker A: PI3K signaling in cancer: Beyond AKT. CurrOpin Cell Biol. 45:62–71. 2017.
30	Zhu S, Jiao W, Xu Y, Hou L, Li H, Shao J, Zhang X, Wang R and Kong D: Palmitic acid inhibits prostate cancer cell proliferation and metastasis by suppressing the PI3K/Akt pathway. Life Sci. 286:1200462021. View Article : Google Scholar : PubMed/NCBI
31	Zhang L, Shao L, Creighton CJ, Zhang Y, Xin L, Ittmann M and Wang J: Function of phosphorylation of NF-kB p65 ser536 in prostate cancer oncogenesis. Oncotarget. 6:6281–6294. 2015. View Article : Google Scholar : PubMed/NCBI
32	Erdogan S, Serttas R, Turkekul K and Dibirdik I: The synergistic anticancer effect of salinomycin combined with cabazitaxel in CD44⁺ prostate cancer cells by downregulating wnt, NF-κB and AKT signaling. Mol Biol Rep. 49:4873–4884. 2022. View Article : Google Scholar : PubMed/NCBI
33	Tian Y, Lei Y, Wang Y, Lai J, Wang J and Xia F: Mechanism of multidrug resistance to chemotherapy mediated by P-glycoprotein (Review). Int J Oncol. 63:1192023. View Article : Google Scholar : PubMed/NCBI
34	Zhu YX, Jia HR, Duan QY and Wu FG: Nanomedicines for combating multidrug resistance of cancer. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 13:e17152021. View Article : Google Scholar : PubMed/NCBI
35	Xu T, Guo P, He Y, Pi C, Wang Y, Feng X, Hou Y, Jiang Q, Zhao L and Wei Y: Application of curcumin and its derivatives in tumor multidrug resistance. Phytother Res. 34:2438–2458. 2020. View Article : Google Scholar : PubMed/NCBI
36	Chen T, Xiao Z, Liu X, Wang T, Wang Y, Ye F, Su J, Yao X, Xiong L and Yang DH: Natural products for combating multidrug resistance in cancer. Pharmacol Res. 202:1070992024. View Article : Google Scholar : PubMed/NCBI